-
1 Comment
International Biotechnology Trust is currently in a long term downtrend where the price is trading 4.0% below its 200 day moving average.
From a valuation standpoint, the stock is 89.8% cheaper than other stocks from the Financial Services sector with a price to sales ratio of 5.4.
International Biotechnology Trust's total revenue sank by 0.0% to $4M since the same quarter in the previous year.
Its net income has dropped by 0.0% to $3M since the same quarter in the previous year.
Finally, its free cash flow fell by 174.4% to $-10M since the same quarter in the previous year.
Based on the above factors, International Biotechnology Trust gets an overall score of 1/5.
Exchange | LSE |
---|---|
CurrencyCode | GBP |
ISIN | GB0004559349 |
Industry | Biotechnology |
Sector | Healthcare |
Beta | 0.34 |
---|---|
Market Cap | 192M |
PE Ratio | 5.35 |
Target Price | None |
Dividend Yield | 5.5% |
International Biotechnology Trust plc specializes in investments in development stage and late stage companies. The majority of the fund's assets are generally invested in smaller and mid-capitalization quoted companies, with a minority in larger capitalization quoted companies. It makes long only investments. It prefers to invest in quoted or unquoted biotechnology and life sciences companies focused on drug discovery and development and in related sectors such as microbiology, life sciences, pharmaceutical research and development, gene research and development, medical devices or healthcare services. The fund seeks to invest in companies engaged in development and/or commercialization of a product, device or enabling technology and also invests in the therapeutic sub-sector. The fund also prefers to invest in companies with strong growth potential from the development and/or commercialization of either a biotechnology drug candidate, medical device or other enabling technology for medical research. It may also invest in specialty pharmaceuticals and life science tools. These companies can range from small private companies with strong science and people that need development funding, to large, multi-billion dollar biotechnology and medical device companies which have portfolios of products, many of which are already used in hospitals, clinics and pharmacies around the world. It makes majority of its investments in smaller and mid-capitalization quoted companies and seeks to invest up to thirty percent of the Company's assets in unquoted companies, while allowing an exposure of up to forty percent in unquoted companies (at the time of investment and after allowing for valuation write-ups and further follow-on investments). The fund typically invests in the United States, but seeks the best investments worldwide and so may also invest in Western Europe, Australia, and Asia. It typically invests between $1 million and $4 million in its portfolio companies. It exits its unquoted investments through the sale of the
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for IBT.LSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025